Equillium (EQ) Competitors $0.41 -0.08 (-16.93%) Closing price 03/28/2025 04:00 PM EasternExtended Trading$0.40 0.00 (-0.10%) As of 03/28/2025 06:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock EQ vs. EDIT, ELUT, RENB, TLSA, ADVM, COYA, CHRS, MIST, FATE, and PROCShould you be buying Equillium stock or one of its competitors? The main competitors of Equillium include Editas Medicine (EDIT), Elutia (ELUT), Renovaro (RENB), Tiziana Life Sciences (TLSA), Adverum Biotechnologies (ADVM), Coya Therapeutics (COYA), Coherus BioSciences (CHRS), Milestone Pharmaceuticals (MIST), Fate Therapeutics (FATE), and Procaps Group (PROC). These companies are all part of the "pharmaceutical products" industry. Equillium vs. Editas Medicine Elutia Renovaro Tiziana Life Sciences Adverum Biotechnologies Coya Therapeutics Coherus BioSciences Milestone Pharmaceuticals Fate Therapeutics Procaps Group Equillium (NASDAQ:EQ) and Editas Medicine (NASDAQ:EDIT) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, profitability, valuation, analyst recommendations, media sentiment, community ranking, risk, institutional ownership and dividends. Does the MarketBeat Community favor EQ or EDIT? Editas Medicine received 277 more outperform votes than Equillium when rated by MarketBeat users. However, 81.82% of users gave Equillium an outperform vote while only 53.23% of users gave Editas Medicine an outperform vote. CompanyUnderperformOutperformEquilliumOutperform Votes3681.82% Underperform Votes818.18%Editas MedicineOutperform Votes31353.23% Underperform Votes27546.77% Do institutionals & insiders hold more shares of EQ or EDIT? 27.0% of Equillium shares are owned by institutional investors. Comparatively, 71.9% of Editas Medicine shares are owned by institutional investors. 30.3% of Equillium shares are owned by insiders. Comparatively, 1.9% of Editas Medicine shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Is EQ or EDIT more profitable? Equillium has a net margin of -10.05% compared to Editas Medicine's net margin of -340.96%. Equillium's return on equity of -20.68% beat Editas Medicine's return on equity.Company Net Margins Return on Equity Return on Assets Equillium-10.05% -20.68% -10.77% Editas Medicine -340.96%-80.13%-50.99% Which has more volatility & risk, EQ or EDIT? Equillium has a beta of 1.87, suggesting that its share price is 87% more volatile than the S&P 500. Comparatively, Editas Medicine has a beta of 1.88, suggesting that its share price is 88% more volatile than the S&P 500. Which has better earnings and valuation, EQ or EDIT? Equillium has higher revenue and earnings than Editas Medicine. Equillium is trading at a lower price-to-earnings ratio than Editas Medicine, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEquillium$45.91M0.31-$13.34M-$0.14-2.90Editas Medicine$32.31M3.21-$153.22M-$2.88-0.43 Does the media favor EQ or EDIT? In the previous week, Equillium had 4 more articles in the media than Editas Medicine. MarketBeat recorded 9 mentions for Equillium and 5 mentions for Editas Medicine. Editas Medicine's average media sentiment score of 0.61 beat Equillium's score of 0.49 indicating that Editas Medicine is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Equillium 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Editas Medicine 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts prefer EQ or EDIT? Equillium presently has a consensus price target of $3.00, suggesting a potential upside of 640.01%. Editas Medicine has a consensus price target of $6.83, suggesting a potential upside of 446.67%. Given Equillium's stronger consensus rating and higher probable upside, equities research analysts plainly believe Equillium is more favorable than Editas Medicine.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Equillium 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50Editas Medicine 2 Sell rating(s) 9 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.07 SummaryEquillium beats Editas Medicine on 11 of the 18 factors compared between the two stocks. Remove Ads Get Equillium News Delivered to You Automatically Sign up to receive the latest news and ratings for EQ and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart EQ vs. The Competition Export to ExcelMetricEquilliumPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$14.36M$6.91B$5.63B$7.83BDividend YieldN/A2.73%4.57%4.00%P/E Ratio-2.907.1723.3318.67Price / Sales0.31220.47388.4691.01Price / CashN/A65.6738.1634.64Price / Book0.636.396.894.23Net Income-$13.34M$142.12M$3.20B$247.15M7 Day Performance-47.55%-5.06%-2.98%-2.17%1 Month Performance-46.93%-7.49%1.63%-5.68%1 Year Performance-82.45%-10.91%9.45%-0.74% Equillium Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)EQEquillium2.899 of 5 stars$0.41-16.9%$3.00+640.0%-82.5%$14.36M$45.91M-2.9040Earnings ReportAnalyst ForecastNews CoverageGap DownEDITEditas Medicine4.0587 of 5 stars$1.39+6.1%$6.83+391.6%-83.2%$115.34M$32.31M-0.54230Analyst RevisionGap UpELUTElutia3.9314 of 5 stars$2.81-3.8%$9.00+220.3%-16.2%$114.47M$24.38M-1.08180Short Interest ↓News CoverageRENBRenovaro1.0766 of 5 stars$0.72+2.6%N/A-78.1%$114.04MN/A-0.7720Positive NewsGap DownTLSATiziana Life Sciences0.6148 of 5 stars$1.08-2.7%N/A+146.7%$113.83MN/A0.008Short Interest ↑Gap UpADVMAdverum Biotechnologies4.4097 of 5 stars$5.40+5.9%$27.83+415.4%-67.4%$112.33M$1M-0.90190Upcoming EarningsInsider TradeNews CoveragePositive NewsCOYACoya Therapeutics2.0456 of 5 stars$6.65-0.4%$17.00+155.6%-33.9%$111.22M$3.55M-10.236Analyst ForecastAnalyst RevisionNews CoverageCHRSCoherus BioSciences3.5863 of 5 stars$0.95-7.6%$5.38+464.5%-64.9%$110.35M$266.96M-11.90330MISTMilestone Pharmaceuticals2.3036 of 5 stars$2.05+7.9%$17.00+729.3%-50.8%$109.38M$1M-2.5330Analyst ForecastNews CoverageGap DownHigh Trading VolumeFATEFate Therapeutics3.8276 of 5 stars$0.94+2.9%$5.50+484.6%-88.4%$107.81M$13.63M-0.57550Positive NewsPROCProcaps GroupN/A$0.95-40.3%N/A-67.2%$107.18M$409.92M0.004,900Gap DownHigh Trading Volume Remove Ads Related Companies and Tools Related Companies Editas Medicine Competitors Elutia Competitors Renovaro Competitors Tiziana Life Sciences Competitors Adverum Biotechnologies Competitors Coya Therapeutics Competitors Coherus BioSciences Competitors Milestone Pharmaceuticals Competitors Fate Therapeutics Competitors Procaps Group Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:EQ) was last updated on 3/29/2025 by MarketBeat.com Staff From Our PartnersA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | SponsoredJust Revealed: The chip company making AI look primitiveIn his just-released video presentation, this renowned market strategist — who's been called "one of the most ...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Equillium, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Equillium With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
